NCT03436862 2023-12-05
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
SCRI Development Innovations, LLC
Phase 2 Completed
Clinical Trials
4 trialsNCT03121534 2023-02-17
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03146468 2021-09-23
NIVALLO
Melbourne Health
Phase 2 Unknown
NCT04439214 2021-04-06
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
National Cancer Institute (NCI)
Phase 2 Completed